<DOC>
	<DOCNO>NCT00086606</DOCNO>
	<brief_summary>This 38-week , randomize , double-blind , placebo-controlled , parallel group trial approximately 150 patient history immediate hypersensitivity reaction peanut protein .</brief_summary>
	<brief_title>A Safety Efficacy Study Xolair Peanut Allergy</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>The patient diagnosis acute peanut allergy The patient meet Xolair dose table eligibility criterion serum baseline IgE level 30 1300IU/mL , body weight 20 150 kilogram The patient six 75 year age The patient react peanut flour wheat ( placebo ) flour first Oral Food Challenge ( OFC ) The patient positive skin prick test peanut detectable serum peanutspecific IgE level The patient able swallow capsule Have FEV1 value &lt; 80 % predict clinical feature moderate persistent asthma , define NHLBI guideline Have significant medical condition ( e.g. , liver , gastrointestinal , kidney , cardiovascular , pulmonary disease , blood disorder ) , , opinion Investigator , make subject unsuitable induction food reaction Have history allergy wheat protein Have previously expose monoclonal antibody treatment</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Peanut</keyword>
</DOC>